blindness and tirzepatide Diabetes: May Lower Risk of Diabetic Retinopathy Study: Link Between Ozempic, Weight

For approved prescription medicines, CanadianInsulin.com operates as a prescription referral platform

Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)

The prolonged open-label lead-in phase allowed for a comprehensive assessment of weight maintenance and provided insights into dose escalation strategies

Others need their full maintenance dose indefinitely